AIRLINK 188.50 Decreased By ▼ -8.15 (-4.14%)
BOP 10.17 Increased By ▲ 0.03 (0.3%)
CNERGY 6.61 Decreased By ▼ -0.08 (-1.2%)
FCCL 34.03 Increased By ▲ 1.01 (3.06%)
FFL 16.60 Decreased By ▼ -0.05 (-0.3%)
FLYNG 24.16 Increased By ▲ 1.71 (7.62%)
HUBC 126.20 Decreased By ▼ -1.09 (-0.86%)
HUMNL 13.82 Decreased By ▼ -0.08 (-0.58%)
KEL 4.82 Increased By ▲ 0.06 (1.26%)
KOSM 6.50 Increased By ▲ 0.13 (2.04%)
MLCF 43.19 Increased By ▲ 0.97 (2.3%)
OGDC 213.00 Decreased By ▼ -0.03 (-0.01%)
PACE 7.30 Increased By ▲ 0.29 (4.14%)
PAEL 42.19 Increased By ▲ 1.32 (3.23%)
PIAHCLA 17.47 Increased By ▲ 0.65 (3.86%)
PIBTL 8.43 Increased By ▲ 0.14 (1.69%)
POWER 9.00 Increased By ▲ 0.18 (2.04%)
PPL 184.90 Increased By ▲ 1.33 (0.72%)
PRL 38.02 Decreased By ▼ -0.25 (-0.65%)
PTC 24.25 Increased By ▲ 0.18 (0.75%)
SEARL 94.75 Decreased By ▼ -0.36 (-0.38%)
SILK 1.00 No Change ▼ 0.00 (0%)
SSGC 39.60 Decreased By ▼ -0.71 (-1.76%)
SYM 17.89 Decreased By ▼ -0.32 (-1.76%)
TELE 8.73 No Change ▼ 0.00 (0%)
TPLP 12.50 Increased By ▲ 0.29 (2.38%)
TRG 63.90 Decreased By ▼ -0.46 (-0.71%)
WAVESAPP 10.50 Increased By ▲ 0.06 (0.57%)
WTL 1.79 No Change ▼ 0.00 (0%)
YOUW 3.98 Decreased By ▼ -0.02 (-0.5%)
BR100 11,721 Decreased By -1.9 (-0.02%)
BR30 35,442 Increased By 83 (0.23%)
KSE100 113,073 Increased By 434.6 (0.39%)
KSE30 35,576 Increased By 117.9 (0.33%)

The pharmaceuticals sector is facing an intensive period of mergers and acquisitions in the coming years, even if US firms Pfizer and Allergan recently failed to tie the knot, the corporate consultancy firm EY said Monday. "We're going to see a high level of investments and divestments in the pharmaceuticals sector in the coming years," said Gerd Stuerz, analyst at EY. In April, Pfizer and Allergan called off a $160-billion (144-billion-euro) tie-up to create a new world leader in pharmaceuticals ahead of Switzerland's Novartis due to a US crackdown on tax-saving mergers. But that is unlikely to signify the end of a wave of major deals in the sector, EY said.
"Companies will sell off entire divisions or buy new ones in order to strengthen their position," said another expert Siegfried Bialojan. In face of fierce competition, external growth is now key for many companies. "Pharmaceutical groups can only present innovations quickly if they buy these from outside," Bialojan argued. After a record year for M&A (mergers and acquisitions) in the pharmaceuticals sector in 2014, 2015 would have been even better if the tie-up between Pfizer and Allergan had materialised. Bialojan predicted that the total market value of M&A deals could soon reach around $200 billion each year. A number of major deals have been signed in recent years. After its failure to acquire Allergan, Pfizer recently announced plans to buy Anacor Pharmaceuticals, a specialist in eczema treatment, for more than $5 billion.
It is also interested in Medivation, a California-based biotechnology firm specialising in cancer treatments that is also coveted by French group Sanofi and US firm Amgen. Also in the United States, Abbott Laboratories and St. Jude Medical, leading makers of heart care and coronary devices, announced a $25 billion merger to better target the rising levels of cardiovascular disease in ageing populations. German pharmaceuticals and chemicals giant Bayer is offering 55 billion euros for Monsanto, a bid the US firm has rejected for now.

Copyright Agence France-Presse, 2016

Comments

Comments are closed.